Technology

Zynerba Pharmaceuticals

$3.58
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

$0.00 (0.00%) Today
$0.00 (0.00%) As of 10:07 AM UTC after-hours

Why Robinhood?

You can buy or sell ZYNE and other stocks, options, and ETFs commission-free!

About ZYNE

Zynerba Pharmaceuticals, Inc. engages in the provision of pharmaceutically-produced transdermal cannabinoid therapies. It focuses on research and development of rare and near-rare neuropsychiatric conditions. It offers Zygel product which formulated as a permeation-enhanced gel for transdermal delivery. The company was founded by Audra L. Stinchcomb on January 31, 2007 and is headquartered in Devon, PA. The listed name for ZYNE is Zynerba Pharmaceuticals, Inc. Common Stock.

CEO
Armando Anido
Employees
28
Headquarters
Devon, Pennsylvania
Founded
2007
Market Cap
106.57M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
1.45M
High Today
$3.65
Low Today
$3.51
Open Price
$3.59
Volume
1.44M
52 Week High
$7.45
52 Week Low
$2.55

Collections

ZYNE Earnings

-$0.78
-$0.52
-$0.26
$0.00
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Mar 9, Pre-Market

You May Also Like

OVCHY
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure